№ files_lp_4_process_3_113691
File format: docx Character count: 8528 File size: 90 KB
Structured form collecting demographic, clinical, and epidemiological information for confirmed mpox cases, including guidance for follow-up and contact tracing by health authorities.
Year: 2024
Country / Region: Ireland
Subject: Mpox case reporting and contact tracing
Document Type: Public health surveillance form
Issuing Authority: Health Protection Surveillance Centre (HPSC)
Author: Not specified
Target Audience: Healthcare providers, Public Health Departments
Date of Issue: 17/09/2024
Version: V5.2
Confidentiality: Confidential
Data Collected: Patient identification, clinical symptoms, vaccination history, previous mpox infection, pregnancy status, HIV status, immunosuppression, clinical care, hospital admission
Purpose: Case investigation and enhanced surveillance of confirmed mpox cases
Links: https://www.hpsc.ie/notifiablediseases/whotonotify/
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
mpox vaccine Patient Group Direction (PGD)
Year: 2024
Region / city: England
Topic: Vaccination
Document type: Patient Group Direction
Organization: UK Health Security Agency (UKHSA)
Author: Christina Wilson, Dr. Mary Ramsay, David Green
Target audience: Registered healthcare practitioners
Period of validity: 10 October 2024 - 30 April 2027
Approval date: 4 October 2024
Amendments date: 9 October 2024
Clinical and Laboratory Testing Guidance for Mpox in Massachusetts, April 2024
Year: 2024
Region: Massachusetts, United States
Document type: Public health advisory
Issuing authority: Massachusetts Department of Public Health
Office: Executive Office of Health and Human Services
Bureau: Bureau of Infectious Disease and Laboratory Sciences
Subject: Mpox clinical guidance, laboratory testing, vaccination, and treatment
Target audience: Healthcare providers, hospitals, community health centers, emergency medical services, local boards of health
Date of issue: April 2, 2024
Disease focus: Mpox (monkeypox virus)
Virus clades referenced: MPXV Clade IIb, MPXV Clade I
Testing facilities: Massachusetts State Public Health Laboratory, commercial laboratories
Treatment referenced: Tecovirimat (TPOXX), STOMP clinical trial, CDC EA-IND protocol
Vaccination referenced: Jynneos vaccine
Epidemiological period covered: October 2023 to March 2024
Report on Mpox Preparedness, Prevention, and Control Engagement with Religious Leaders, Harbor Masters, Recipients of Care (People Living with HIV), Commercial Sex Workers & Gay Community, and Traditional Healers
Year: 2024
Region / City: Sierra Leone
Theme: Mpox Preparedness and Community Engagement
Document Type: Report
Organization / Institution: National Public Health Agency
Author: Risk Communication and Community Engagement Pillar
Target Audience: Religious Leaders, Harbor Masters, People Living with HIV, Commercial Sex Workers, Gay Community, Traditional Healers
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
WHO/Europe Launches Mpox Toolkit Developed with Leadership from Kristiania Research Centre
Year: 2026
Region / City: Oslo, Norway
Theme: Public Health, Crisis Communication, Community Engagement
Document Type: Press Release
Organization: WHO/Europe, Kristiania University of Applied Sciences
Author: Professor Audra Diers-Lawson
Target Audience: Public health authorities, ministries, NGOs, international agencies, civil society
Period of Validity: N/A
Date of Approval: February 5, 2026
Date of Changes: N/A
Mpox screening form for healthcare facility entrances
Year: 2023
Region / city: Not specified
Topic: Healthcare, Infection Control
Document type: Screening form
Institution: Healthcare facility
Author: Not specified
Target audience: Healthcare workers, patients, visitors
Validity period: Not specified
Approval date: Not specified
Amendment date: Not specified
Outreach mpox vaccination at sex-on-premises venues in Sydney: An audit of a collaborative intervention by public health nurses and LGBTQI+ peer workers
Year: 2024
Region / City: Sydney, New South Wales, Australia
Topic: Mpox vaccination and public health outreach
Document Type: Research audit
Institutions: Kirketon Road Centre, ACON, NSW Health, University of Technology Sydney, UNSW Sydney
Authors: Vendula Belackova, Anna Doab, Joubert van der Merwe, Nicole Christie, Sandra Chaverot, Matthew Vaughan, Ian Anderson, Bruce Taylor, John Kearley, Wendy Machin, Bianca Prain, Phillip Read
Ethics Approval: SESLHD Low Negligible Risk Committee, 25 February 2025
Data Source: Routinely collected clinical and administrative records
Vaccination Sites: Fixed-site (KRC) and sex-on-premises venues (SOPVs)
Population: MSM (men who have sex with men) attending SOPVs
Number of Vaccinations: 639 at fixed-site; 407 at SOPVs
Study Period: 2024
Funding: Internal resources of KRC and ACON
Key Methods: Descriptive, comparative, and multivariate analysis of vaccination records matched with Australian Immunisation Register
Topics: V52 17092024 mpox